Stock AARTIDRUGS AARTI DRUGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Aarti Drugs Limited NSE India S.E.

Equities

AARTIDRUGS

INE767A01016

Market Closed - NSE India S.E.
Other stock markets
 07:42:29 2024-04-30 am EDT 		5-day change 1st Jan Change
504.6 INR -0.49% Intraday chart for Aarti Drugs Limited +2.27% +3.14%
Mar. 29 Aarti Drugs Limited Announces Executive Cessation CI
Jan. 31 Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • With a 2024 P/E ratio at 26.98 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AARTI DRUGS LIMITED Stock Aarti Drugs Limited
+3.14% 556M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
A+
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AARTIDRUGS Stock
  4. AARTIDRUGS Stock
  5. Ratings Aarti Drugs Limited